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with no evidence of disease. Flow cytometry shows no aberrant 
populations. Cytogenetic testing is pending at this report. HTLV 
1 viral load studies show consistent decrease in viral load. The 
patient is enjoying an active life with no significant post transplant 
adverse ffects. 
GVH/GVL 
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HOST-REACTIVE MEMORY T LYMPHOCYTES ALONE DO NOT INDUCE 
MORE SEVERE GRAFT-VERSUS-HOST DISEASE 
Chert, B.J.; Cui, X.; C,~ao, N.J. Dltke U, ivevsity Medical Center, 
Din'ham, NC. 
Memo W T lylnphocytes are thought o mediate more rapid and 
profound memory irnmunc response. In this study, we tested 
whether it is true in graft-versus-host disease (GVHD). C57BL/6 
mice (H2 b) were injected with irradiated BALB/c (H2 d) spleen 
cells intraperitoneally at least 8 weeks before they were used as 
immunized onors. Splenic T cells (>90% pure) were harvested 
from these immunized animals and separated into CD62L + (>90% 
pure) and CD62L- (>99% pure) populations by magnetic beads. 
CD62L + T cells include both naive and memory T cells, while 
CD62L- T cells contain memory T cells but no naive T cells. We 
next compared the alloreactivity and the ability to induce GVHD 
(C57BL/6 to BALB/c) of CD62L T cells with those of unseparat- 
ed and CD62L + T cells. Despite CD62L (memory) T cells con- 
tain similar numbers of interferon-y-secreting cells upon response 
to host antigens as detected by enzyme-linked immunospot assay, 
CD62L- T cells had dramatically decreased ability to induce 
GVHD in BALB/e mice compared to unseparated and CD62L + T 
cell controls (Table). However, CD62L T cell recipients did 
develop GVHD as documented by weight loss (Table) and histo- 
logic changes. Similar results were observed when the mice immu 
nized with BCL1 cells (a BALB/c-or igin B cell 
lymphoma/leukelnia cell line) were used as donors. We conclude 
that host-reactive m mm T T cells alone have decreased ability to 
induce GVHD compared with a mixture of naive and memory T
cells. Memory T cells obtained from tumor cel l - immunized 
donors may be a unique source of T cells for tumor imnmnothera- 
py because they do not induce severe GVHD. 
~%.Sur,va Surviwd %Weiuht loss 
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A CRITICAL ROLE FOR CD4+CD25 ÷ SUPPRESSOR CELLS IN CON- 
TROLLING GVHD AFTER DLI IN MURINE BONE MARROW CHIMERAS 
Xia, G., Yah, X.; Cao, 0.; T77titt, R.L.; Johnson, B.D. Depmv:me,t of 
Pediatrics, ~Iedit:al College of IUisconsi{z, 3/lilwzzkee, ~Z 
A murine model of allogeneic bone marrow (BM) transplanta- 
tion (C57BL/6[B6]-into-AKR/J) was used to further define the 
role of CD4+CD25 * T cells in controling GVHD after DLI and 
their potential  therapeutic application. B6- into-AKR BM 
chimeras were depleted of CD25 + cells in vivo with anti-CD25 
mAb or transplanted with BM from CD25 K° donors so that the 
BM recipients would be devoid of donor-derived CD25 + cells. 
Depletion of CD25 + cells in vivo (>70% depletion) significantly 
increased the severity of DLI- induced GVHD as indicated by 
body weight loss and increased mortality as compared to nonde- 
pleted control mice. GVHD was even more intense in mice trans- 
planted with CD25 k° BM. Enhanced GVHD after CD25 deple- 
tion was seen after DLI of either 30 million or 60 million donor 
splenocytes. To test the ability of CD25 ~ cells to persist and 
expand in vivo, nylon-wool enriched, immunomagnetically select- 
ed fresh CD25 ÷ cells were adoptively transferred into syngeneic 
nude mice. These cells progressively expanded (CD4 and CD8 
subsets) over 5 months in syngeneic nude mice. Approximately 
30% of the cells at 2-wk and less than 10% at 20-wk were still 
CD25 *. Various conditions for activation and expansion of CD25+ 
suppressor cells were examined. Freshly-isolated B6 CD25 ÷ cells 
were cultured with rIL-2 in the presence of (1) immoblized anti- 
CD3 mAb plus soluble anti-CD28 mAb, (2) magnetic beads coat- 
ed with anti-CD3 and anti-CD28 mAbs, and (3) CD32/4-1BB lig- 
and double-transfected K562 tmnor cells (K562DT) "loaded" 
with anti CD3 and anti-CD28 mAbs. The K562DT cells induced 
superior short-term expansion of CD4+CD25+cells (>10 fold after 
7-10 days of culture). Imnmblized anti-CD3 plus soluble anti- 
CD28 preferentially expanded the CD8 subset from <3% in fresh 
CD25+cells to >75% of the total cells after 1 week of culture. Ex 
vivo expanded CD25 ÷ cells were more suppressive than fresh cells 
added to primary mixed lymphocyte cultures in which 50% of 
stimulation inhibition was achieved at a 1:8 CD25*/CD25 ratio 
for ex vivo expanded CD25 + as compared to a 1:1 ratio required 
for fresh cells. Studies looking at the ability of ex vivo expanded 
CD25 + ceils to persist/expand in vivo, and the GVHD-protective 
role of freshly-isolated versus ex vivo expanded CD25" cells coad- 
ministered with DLI, are in progress. 
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TCR TRANSGENIC HEMATOPOETIC STEM CELLS ENGRAFT INTO 
NON-TRANSGENIC RECIPIENTS AND EVOLVE ANTIGEN-SPECIFIC 
T-CELLS 
Krnft, D.L.; Ranheim, E.A.; Weissman, I.L. Pediatric 
Hematology/Oncology and Dept of Pathology, Sta~zfo'rd University 
School of ~/ledicine, Staj~'ord, CA. 
We hypothesized that genetically modified hematopoetic stem 
cells (HSC) transduced with a specific tmnor antigen specific 
TCR may, when given as a fraction of a donor hematopoetic 
sten, cell graft, lead to engraftment of tumor antigen specific T-  
cells and facilitate directed Graft vs Malignancy (GVL). ~¢\7e are 
developing a model system for exploring the feasibility of this 
approach. An important component of evaluating such a strategy 
is determining the ability for donor TCR-transgenic HSC to 
engraft into non-transgenic recipients, and to determine the 
ldneties of antigen specific T-cell  engraftment. P14 mice are 
transgenic for the elass-I restricted TCR specific to LCMV-Gly- 
coprotein-33. Bone marrow was obtained from P14 CD45.2 
TCR-Transgenic mice and transplanted into lethally irradiated 
non-transgenic, ongenic CD45.1 recipients. Of the 500, 000 
marrow cells in the graft, 0%, 10%, 25%, 50% or 100% was 
from a P14 donor, the remainder from CD45.1 congenic mar- 
row. The number of LCMV-GP33 specific T-cells in the periph- 
eral blood was measured weekly with MHC-H-2  D(b)GP33 
tetramer. Control P14 mice contained an average of 25% CD8+ 
cells in the peripheral blood, of which 82% were GP33 tetramer 
positive. We found that TCR-transgenic  P14 bone marrow 
would engraft, and result in measurable donor derived LCMV- 
GP specific CD8+ T-cells. The fraction of tetramer positive T- 
ceils in peripheral blood increased in correlation to the percent- 
age of P 14 bone marrow transplanted. Four weeks post-transplant 
CD45.2, tetramer+ T-cells made up a mean 3.5% of peripheral 
bloo.d in mice which had received 100% P14 donor marrow, 
1.3% from 50% P14 donor, and .63% from a 25% P14 marrow 
donor. By week five, tetramer + cells had increased to 9.4% of 
blood cells in mice receiving 100% P14 donor marrow, 4.7% 
from 50% P14 marrow and .74% from 25% donor. Engraftment 
of tetramer+ T-cel ls increased in weeks 5 and 6 and then 
remained stable. 7 weeks post transplant in mice receiving 50% 
P14 marrow, 8.8% of peripheral cells were CD8+, of which 
43.7% were tetramer+. 25% P14 transgenic donor recipients 
evolved 5.5% CD8+ T-cells of which 7.8% were tetramer posi- 
tive. These results suggest hat bone marrow containing TCR- 
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transgenic HSC can engraft and evolve significant numbers of 
antigen specific T-cclls, which may in the future be utilized for 
targeted antigen specific GVL. 
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RESIDUAL HOST CHIMERISM AND PATTERN OF ANTIGEN EXPRES- 
SION INFLUENCE THE FATE OF ADOPTIVELY TRANSFERRED ALLO- 
GENIC T CELLS 
Dzlra/eovic, N.; F:/chs, E.J.; Lz:zJdk, L. The Si,lm 7 RTm::zel Comp're- 
he~zsive Cavce'r CeJl~e:" at ffoh:zs Hopleilzs, B,zlti1~lo:'e, MD. 
Donor lymphocyte infusions (DLI) and allogeneic T cells spe- 
cific for defined lninor histocompatibility antigen (±HAg) are 
increasingly used in the treatment of relapsed malignancies after 
allogeneic BMT. However, the fate and function of adoptively 
transferred T cells are poorly understood. To evaluate the role of 
host chimerism, complete and mixed chimeras were constructed 
by transplanting DBA/2 mice (H-2 d) with bone marrow (BM) 
from MHC-mismatched C56BL/6 (H-2 t') donors after myeloabla- 
tive and non-myeloablative conditioning, respectively. Three 
weeks later, both sets of chimeras received CFSE-labeled B6.SJL 
T ceils, which uniquely express the CD45.1 allele. On day 6 and 
10 after DLI administration, 86% and 93% of CD45.I + T ceils in 
mixed chimeras, respectively, and 41% and 63% of CD45.1 + T 
cells in full donor chimeras, respectively, underwent more than 7 
divisions. Serial monitoring of CD45.1 + T cells in full donor 
chimeras revealed that 28% of these cells remain undivided for 
more than 20 days. To define the effect of targeted antigen tissue 
expression pattern on the fate of allogeneic antigen-specific T 
cells, we used transgenic mice with wide (HA104) or pancreas- 
restricted (Ins-HA) expression of hemaglutinin (HA). TCR trans- 
genic Clone 4 (CL4) mice, which contain H-2K ~1 restricted CD8 + 
T cells specific for HA peptide were used as a source of antigen- 
specific T ceils. HA104 or Ins-HA mice on BALB/c background 
underwent BMT from MHC-compatible B10.D2 donors, fol- 
lowed by DLI from TCR transgenic B10.D2-CL4 mice three 
weeks later. Differential expression of the Thy 1.1 ÷ antigen on 
transgenic T cells was used for in vivo monitoring of their fate. 
Adoptively transferred TCR-specific transgenic CD8 ÷ T-cells 
engrafted, expanded, and then sharply declined and became unde- 
tectable in the mice with wide distribution of targeted HA anti- 
gen. In contrast, transgenic T ceils expanded but remained 
detectable for at least 30 days in the animals with pancreas- 
restricted HA expression without causing diabetes. However, co- 
administration of vaccinia virus expressing HA together with 
transgenic T cells resulted in diabetes. In conclusion, residual host 
chimerism, targeted antigens pattern of expression and antigen 
specific vaccinations have a potential to influence the late of adop- 
tively transferred allogeneic T-cells. 
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DONOR PRETREATMENT WITH G-CSF PREVENTS CHRONIC 
GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL 
TRANSPLANTATION 
z!/lacDol~alcl, I~P.I ; Rowe, V.1; Filippich, C J; CloustoJz, A.D.2; Fe:/'alrl, 
ff.L.S; Hill, G.R3 1. The Quee*zslmzd bzstitzlte of Medical Research, 
B:'isbmze, QLD, Azlst,-alia; 2. UMve'rsity of Qaee*Tslalzd, Bvisbmze, 
OLD, Az:st/:alia; 3. UMversit~, of Michigal~, Amz AT"l, or, ~/II. 
The incidence of extensive chronic GVHD (cGVHD) after 
allogeneic stem cell transplantation with G-CSF mobilised 
peripheral blood stem cell (PBSC) products is increased com- 
pared to that after bone *narrow transplantation a d necessitates 
prolonged, expensive and poorly effective immunosuppressive 
therapy. G-CSF is known to alter T cell function and PBSC 
products contain i0-20 times the number of T cells relative to 
bone marrow grafts, both of which may increase cGVHD. We 
have studied the effects of G-CSF and T cell dose on cGVHD in 
two well-described models manifested by either immune complex 
glomerulonephritis (DBA/2-+B6D2F1) or sclerodermatous 
hepatic and cutaneous fibrosis (Bl0.D2-+Balb/c). The former 
model induces GVHD to major and minor HA and the latter to 
minor HA only. Donor mice were treated with G-CSF (2ug/day) 
or diluent for 6 days and recipient mice were transplanted with 
unseparated donor splenocytes that contained equal numbers of 
T cells. In the immune complex model, 80% of SCT recipients 
that received grafts from control treated onors develop nephrot 
ic syndrome compared to 25% in the recipients of G-CSF treat- 
ed grafts (P<0.01) and mortality was decreased from 45 % to I5 % 
(P<0.05). Donor T cell engraftment and B cell activation (class II 
expression) were equivalent in both groups. The reduction in 
cGVHD following donor G-CSF pretreatment occurred in the 
setting of donor Th2 differentiation manifested by reduced inter- 
feron- 7 and increased IL 4 production with a concomitant 100- 
fold increase in the ratio of IgGl:IgG2c~ auto-antibody titres 
(P<0.05). In the scleroderma model, the effect of a 5-fold escalat- 
ed donor G-CSF T cell dose (G-CSF-high T) was compared to 
the low T cell dose (G-CSF-Iow T and control-low T), to mirror 
the effect of the high T cell doses transferred uring clinical 
peripheral blood stem cell transplantation. Hepatic and cuta- 
neous selni-qnantitative histopathology demonstrate hat sclero- 
dermatous cGVHD, characterised by epidermal thickening, 
fibrosis and procollagen deposition, is associated with high T cell 
doses but not G-CSF and Th2 differentiation per se (see table; 
*P<0.05, **P<0.01 v control). Thus, the limitation of T cell doses 
transferred uring PBSCT should reduce chronic GVHD con> 
pared to BMT, whilst maintaining the b neficial effects on graft 
quality. 
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DELAYED INFUSION OF DONOR CD4+25 + T CELLS CONTROLS 
GRAFT-VERSUS-HOST DISEASE WHILE ALLOWING AN EFFECTIVE 
GRAFT-VERSUS-LEUKEMIA RESPONSE 
Jom, s, S.C. ~; Mm'p,by, G. 2,Ko,r,,gold, R.1 . Thomas Jefferso~z Uzziversi- 
U, Kimmel Grocer blstitzLte, Philadelphia, PA; 2. ffeff'ersml Medical 
College, Dept of A*~atoJT~v, Pathology reed Cell Biolog3,, Philadelphia, PA. 
Following allogeneic hematopoietic cell transplantation (HCT), 
the high inverse correlation between graft-versus-host disease 
(GVIID) and leukemic relapse requires that calculated measures 
be taken to reduce GVHD pathology while retaining the graft- 
versus-leukemia effect (GVL). We sought o determine whether 
donor CD4+CD25 + regulatory T cells could control ongoing 
GVHD, effectively providing a window of time whereby the 
GVIt response is permitted to begin in favor of the elimination of 
residual leukemia ceils, before being brought under regulation to 
prevent he full development of lethal GVHD. Prevention of 
lethal GVHD by infusion of donor CD4+CD25 ÷ "F ceils early 
post-HCT (day 2) could be achieved across an MHC barrier in 
the haploidentical C3H into (B6xC3H)F1 model. However, in 
vitro pre-sensitization f donor CD4+CD25 ÷ T cells to recipient 
type alloantigen with high dose IL 2 was required for successful 
regulation. In contrast, in the minor histocompatabiIity antigen 
(miHA)-disparate, CDS-mediated B I0.BR into CBA GVHD 
model, lethal disease could be completely prevented by a single 
injection of freshly isolated donor CD4+CD25 + T cells, given as 
late as 10 days post-HCT. Of importance, this later regulato W 
effect required a CD4~CD25 + to effector CD8 ratio of only 1:3, 
indicating a strong potential for the delayed infusion of 
CD4+CD25 + T cells to control GVHD across miHA barriers. 
Furthermore, this regulation did not prevent complete and 
durable donor engraftment of the hematopoetic compartment. Of 
most significance, the day 10 infusion of donor CD4+CD25 + T 
cells into CBA HCT recipients that had been challenged with the 
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